Targeting oncogenic KRAS with molecular brush-conjugated antisense oligonucleotides
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
The mutant form of the guanosine triphosphatase (GTPase) KRAS is a key driver in human tumors but remains a challenging therapeutic target, making KRAS MUT cancers a highly unmet clinical need. Here, we report a class of bottlebrush polyethylene glycol (PEG)–conjugated antisense oligonucleotides (ASOs) for potent in vivo KRAS depletion. Owing to their highly branched architecture, these molecular nanoconstructs suppress nearly all side effects associated with DNA–protein interactions and substantially enhance the pharmacological properties of the ASO, such as plasma pharmacokinetics and tumor uptake. Systemic delivery to mice bearing human non–small-cell lung carcinoma xenografts results in a significant reduction in both KRAS levels and tumor growth, and the antitumor performance well exceeds that of current popular ASO paradigms, such as chemically modified oligonucleotides and PEGylation using linear or slightly branched PEG. Importantly, these conjugates relax the requirement on the ASO chemistry, allowing unmodified, natural phosphodiester ASOs to achieve efficacy comparable to that of chemically modified ones. Both the bottlebrush polymer and its ASO conjugates appear to be safe and well tolerated in mice. Together, these data indicate that the molecular brush–ASO conjugate is a promising therapeutic platform for the treatment of KRAS -driven human cancers and warrant further preclinical and clinical development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Additional emerging modalities include RNA-targeted therapeutics, antisense oligonucleotides, siRNA-based suppression [65,66], neoantigen vaccines [67,68], and adoptive T-cell therapies targeting mutant KRAS-derived epitopes [69,70].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [65]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular dynamics with coupling to an external bath
Berendsen, H. J. C., Postma, J. P. M., van Gunsteren, W. F., DiNola, A., & Haak, J. R. (1984) · The Journal of Chemical Physics · doi:10.1063/1.448118 · Cited by 30,700 · cited 1×
“The temperature was controlled at 310 K using the Berendsen thermostat while the pressure was controlled at 1 atm using the Berendsen barostat (57).”
MethodGROMACS: Fast, flexible, and free
Van Der Spoel, D., Lindahl, E., Hess, B., Groenhof, G., Mark, A. E., & Berendsen, H. J. C. (2005) · Journal of Computational Chemistry · doi:10.1002/jcc.20291 · Cited by 19,182
The MARTINI Force Field: Coarse Grained Model for Biomolecular Simulations
Marrink, S. J., Risselada, H. J., Yefimov, S., Tieleman, D. P., & de Vries, A. H. (2007) · The Journal of Physical Chemistry B · doi:10.1021/jp071097f · Cited by 5,562
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431 · cited 1×
“Importantly, the observed physiochemical and biopharmaceutical enhancements over naked nucleic acids are realized using predominantly PEG, which is generally regarded as safe for therapeutic applications (37).”
BackgroundExosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
Kamerkar, S., LeBleu, V. S., Sugimoto, H., Yang, S., Ruivo, C. F., Melo, S. A., Lee, J. J., & Kalluri, R. (2017) · Nature · doi:10.1038/nature22341 · Cited by 2,639 · cited 1×
“The difficulty in developing small-molecule inhibitors for KRAS has heightened the importance of alternative methods targeting the oncogene, for example using antisense oligonucleotides (ASOs) (10), which offer a possibility to yield drugs for targets that have proven to be intractable to traditional drug modalities (…”
BackgroundK-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557 · cited 1×
“However, in 2013, it was shown that the cysteine residue of the G12C mutant give rise to a new pocket that can be selectively targeted by small-molecule binders (3, 7).”
BackgroundOncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
Self-citationAdvances in oligonucleotide drug delivery
Roberts, T. C., Langer, R., & Wood, M. J. A. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0075-7 · Cited by 2,027
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
RAS Proteins and Their Regulators in Human Disease
Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943 · cited 1×
“The missense mutation of KRAS aberrantly activates the protein into a hyperexcitable state by attenuating its guanosine triphosphatase (GTPase) activity, which results in an accretion of GTP-bound, activated KRAS and persistent activation of downstream signaling pathways (2).”
BackgroundSynthetic DNA delivery systems
Luo, D., & Saltzman, W. M. (2000) · Nature Biotechnology · doi:10.1038/71889 · Cited by 1,626
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
Ng, E. W. M., Shima, D. T., Calias, P., Cunningham, E. T., Guyer, D. R., & Adamis, A. P. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1955 · Cited by 1,588 · cited 2×
“Additionally, a Y-shaped PEG (40 kDa), which has been adopted in the oligonucleotide drug, pegaptanib (brand name Macugen) (40), is used to form an ASO conjugate as a polymer architecture control.”
BackgroundThe chemical evolution of oligonucleotide therapies of clinical utility
Khvorova, A., & Watts, J. K. (2017) · Nature Biotechnology · doi:10.1038/nbt.3765 · Cited by 1,216 · cited 2×
“On the other hand, nucleic acid modification chemistries have been far more successful for clinical translation, with all currently approved oligonucleotide drugs adopting one or more forms of modifications (24, 25).”
BackgroundRAS-targeted therapies: is the undruggable drugged?
Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103
Love, J. A., Morgan, J. P., Trnka, T. M., & Grubbs, R. H. (2002) · Angewandte Chemie International Edition · doi:10.1002/1521-3773(20021104)41:21<4035::aid-anie4035>3.0.co;2-i · Cited by 920 · cited 1×
“Modified second-generation Grubbs catalyst was prepared based on a published method shortly prior to use (54).”
MethodEssential role for oncogenic Ras in tumour maintenance
Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O'Hagan, R., Pantginis, J., Zhou, H., et al. (1999) · Nature · doi:10.1038/22788 · Cited by 875
The delivery of therapeutic oligonucleotides
Juliano, R. L. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw236 · Cited by 854
Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides
Geary, R. S., Norris, D., Yu, R., & Bennett, C. F. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.008 · Cited by 845 · cited 1×
“However, although nonspecific binding between PS and serum proteins improves tissue uptake and reduces renal clearance, the blood pharmacokinetics (PK) of PS drugs remains very poor (27, 28).”
BackgroundAntisense technology: an overview and prospectus
Crooke, S. T., Baker, B. F., Crooke, R. M., & Liang, X.-H. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00162-z · Cited by 775
Kozma, G. T., Shimizu, T., Ishida, T., & Szebeni, J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.024 · Cited by 696
Phosphorothioates, Essential Components of Therapeutic Oligonucleotides
Eckstein, F. (2014) · Nucleic Acid Therapeutics · doi:10.1089/nat.2014.0506 · Cited by 684 · cited 2×
“, membrane and serum proteins), which ultimately results in high endocytosis but also increased the potential for off-target effects in vivo (26).”
BackgroundNucleic Acid Therapeutics Using Polyplexes: A Journey of 50 Years (and Beyond)
Lächelt, U., & Wagner, E. (2015) · Chemical Reviews · doi:10.1021/cr5006793 · Cited by 600
Fisher, G. H., Wellen, S. L., Klimstra, D., Lenczowski, J. M., Tichelaar, J. W., Lizak, M. J., Whitsett, J. A., Koretsky, A., & Varmus, H. E. (2001) · Genes & Development · doi:10.1101/gad.947701 · Cited by 582
Cellular uptake and trafficking of antisense oligonucleotides
Crooke, S. T., Wang, S., Vickers, T. A., Shen, W., & Liang, X.-H. (2017) · Nature Biotechnology · doi:10.1038/nbt.3779 · Cited by 582 · cited 1×
“in the appropriate intracellular compartments (43).”
Mechanism for the endocytosis of spherical nucleic acid nanoparticle conjugates
Choi, C. H. J., Hao, L., Narayan, S. P., Auyeung, E., & Mirkin, C. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305804110 · Cited by 533 · cited 1×
“The results indicate energy-dependent, mixed uptake mechanisms that likely involve macropinocytosis and clathrinmediated endocytosis (45, 46) (SI Appendix, Fig.”
BackgroundMechanism of oligonucleotide uptake by cells: involvement of specific receptors?
Yakubov, L. A., Deeva, E. A., Zarytova, V. F., Ivanova, E. M., Ryte, A. S., Yurchenko, L. V., & Vlassov, V. V. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.17.6454 · Cited by 509
The Medicinal Chemistry of Therapeutic Oligonucleotides
Wan, W. B., & Seth, P. P. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00551 · Cited by 429 · cited 1×
“On the other hand, nucleic acid modification chemistries have been far more successful for clinical translation, with all currently approved oligonucleotide drugs adopting one or more forms of modifications (24, 25).”
BackgroundMechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides
Juliano, R., Alam, M. R., Dixit, V., & Kang, H. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn342 · Cited by 429
Therapeutic strategies to target RAS-mutant cancers
Ryan, M. B., & Corcoran, R. B. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0105-0 · Cited by 420 · cited 2×
“Nonetheless, the G12C mutation only occurs in a small percentage of KRAS cancers—predominantly in lung adenocarcinomas and, at a lower frequency, in colorectal cancer and pancreatic ductal adenocarcinomas (44%, 11%, and 3%, respectively) (1, 9).”
BackgroundLee, H., de Vries, A. H., Marrink, S.-J., & Pastor, R. W. (2009) · The Journal of Physical Chemistry B · doi:10.1021/jp9058966 · Cited by 398
RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs
Bajan, S., & Hutvagner, G. (2020) · Cells · doi:10.3390/cells9010137 · Cited by 393
Delivery of oligonucleotide‐based therapeutics: challenges and opportunities
Hammond, S. M., Aartsma‐Rus, A., Alves, S., Borgos, S. E., Buijsen, R. A. M., Collin, R. W. J., Covello, G., Denti, M. A., Desviat, L. R., Echevarría, L., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013243 · Cited by 388
Koller, E., Vincent, T. M., Chappell, A., De, S., Manoharan, M., & Bennett, C. F. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr089 · Cited by 281 · cited 1×
“However, although nonspecific binding between PS and serum proteins improves tissue uptake and reduces renal clearance, the blood pharmacokinetics (PK) of PS drugs remains very poor (27, 28).”
BackgroundDNA Nanostructure-Programmed Like-Charge Attraction at the Cell-Membrane Interface
Ding, H., Li, J., Chen, N., Hu, X., Yang, X., Guo, L., Li, Q., Zuo, X., Wang, L., Ma, Y., et al. (2018) · ACS Central Science · doi:10.1021/acscentsci.8b00383 · Cited by 259 · cited 1×
“The results indicate energy-dependent, mixed uptake mechanisms that likely involve macropinocytosis and clathrinmediated endocytosis (45, 46) (SI Appendix, Fig.”
BackgroundFunctionalization of Micelles and Shell Cross-linked Nanoparticles Using Click Chemistry
O'Reilly, R. K., Joralemon, M. J., Wooley, K. L., & Hawker, C. J. (2005) · Chemistry of Materials · doi:10.1021/cm051047s · Cited by 251 · cited 1×
“pling with dibenzocyclooctyne (DBCO)-modified ASO strands via the strain-promoted copper-free click chemistry (41),”
MethodShieh, P., Nguyen, H. V.-T., & Johnson, J. A. (2019) · Nature Chemistry · doi:10.1038/s41557-019-0352-4 · Cited by 233
Therapeutic nucleic acids: current clinical status
Sridharan, K., & Gogtay, N. J. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12987 · Cited by 231
Ross, S. J., Revenko, A. S., Hanson, L. L., Ellston, R., Staniszewska, A., Whalley, N., Pandey, S. K., Revill, M., Rooney, C., Buckett, L. K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal5253 · Cited by 177 · cited 3×
“The difficulty in developing small-molecule inhibitors for KRAS has heightened the importance of alternative methods targeting the oncogene, for example using antisense oligonucleotides (ASOs) (10), which offer a possibility to yield drugs for targets that have proven to be intractable to traditional drug modalities (…”
BackgroundResultAntisense Drug Discovery and Development
Yamamoto, T., Nakatani, M., Narukawa, K., & Obika, S. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.2 · Cited by 158
Graham, M. J., Crooke, S. T., Monteith, D. K., Cooper, S. R., Lemonidis, K. M., Stecker, K. K., Martin, M. J., & Crooke, R. M. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37605-0 · Cited by 140
Inhibition of Coagulation by a Phosphorothioate Oligonucleotide
HENRY, S. P., NOVOTNY, W., LEEDS, J., AULETTA, C., & KORNBRUST, D. J. (1997) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1997.7.503 · Cited by 123
Henry, S. P., Bolte, H. F., Auletta, C. S., & Kornbrust, D. J. (1997) · Toxicology · doi:10.1016/s0300-483x(97)03661-5 · Cited by 118 · cited 1×
“In fact, PS show increased potential for nonspecific adverse effects including induction of stress responses, prolongation of activated partial thromboplastin time, thrombocytopenia, and increased serum transaminase activities (30, 31).”
BackgroundOligonucleotide Therapeutics: Chemistry, Delivery and Clinical Progress
Sharma, V. K., & Watts, J. K. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.144 · Cited by 109
Providing Oligonucleotides with Steric Selectivity by Brush-Polymer-Assisted Compaction
Lu, X., Tran, T.-H., Jia, F., Tan, X., Davis, S., Krishnan, S., Amiji, M. M., & Zhang, K. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b08069 · Cited by 102 · cited 2×
“Two monomers, norbornenyl bromide and norbornenyl PEG, were synthesized following previously reported procedures (33).”
BackgroundMethodSelf-citationLinnane, E., Davey, P., Zhang, P., Puri, S., Edbrooke, M., Chiarparin, E., Revenko, A. S., Macleod, A. R., Norman, J. C., & Ross, S. J. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz214 · Cited by 101
Bottlebrush-architectured poly(ethylene glycol) as an efficient vector for RNA interference in vivo
Wang, D., Lin, J., Jia, F., Tan, X., Wang, Y., Sun, X., Cao, X., Che, F., Lu, H., Gao, X., et al. (2019) · Science Advances · doi:10.1126/sciadv.aav9322 · Cited by 74 · cited 1×
“, coagulopathy and unwanted immune system activation), while substantially improving the plasma PK and concentration in nonliver organs (36).”
BackgroundSelf-citationTheory of Polymer–Nanopore Interactions Refined Using Molecular Dynamics Simulations
Balijepalli, A., Robertson, J. W. F., Reiner, J. E., Kasianowicz, J. J., & Pastor, R. W. (2013) · Journal of the American Chemical Society · doi:10.1021/ja4026193 · Cited by 72
Pharmacokinetics and Proceedings in Clinical Application of Nucleic Acid Therapeutics
Herkt, M., & Thum, T. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.11.008 · Cited by 56
Jia, F., Lu, X., Tan, X., Wang, D., Cao, X., & Zhang, K. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201610753 · Cited by 54 · cited 1×
“The bottlebrush architecture of the pacDNA conceals the ASO within an intermediate-density PEG environment, which provides the ASO with sterics-based selectivity: Hybridization with a complementary strand is unaffected, but access by proteins, which are much larger in cross-section diameter, is significantly hindered…”
BackgroundSelf-citationJia, F., Lu, X., Wang, D., Cao, X., Tan, X., Lü, H., & Zhang, K. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b05064 · Cited by 51
Self-citationWang, D., Lu, X., Jia, F., Tan, X., Sun, X., Cao, X., Wai, F., Zhang, C., & Zhang, K. (2017) · Chemistry of Materials · doi:10.1021/acs.chemmater.7b03520 · Cited by 41
Self-citationEfficacy and safety of mipomersen sodium (Kynamro)
Hovingh, K., Besseling, J., & Kastelein, J. J. P. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.793670 · Cited by 37 · cited 1×
“Mipomersen, the first systemically administered PS drug that treats homozygous familial hypercholesterolemia, was only approved in the United States and not Europe due to concerns of adverse toxic effects (32).”
BackgroundWang, Y., Wang, D., Jia, F., Miller, A. D., Tan, X., Chen, P., Zhang, L., Lü, H., Yang, F., Kang, X., et al. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c13995 · Cited by 29
Self-citationRosell, R., Aguilar, A., Pedraz‐Valdunciel, C., & CHAIB-OUKADOUR, I. (2021) · Nature Cancer · doi:10.1038/s43018-021-00289-3 · Cited by 23 · cited 6×
“Collectively, these data demonstrate that systemic delivery of pacDNAs in preclinical models of KRASMUT NSCLC can achieve potent KRAS down-regulation and selective antitumor activity at a significantly lower dosage than what is previously possible, while using natural, unmodified oligonucleotides.”
InfluentialJia, F., Wang, D., Lu, X., Tan, X., Wang, Y., Lü, H., & Zhang, K. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b03662 · Cited by 22
Self-citationLi, H., Li, Y., Xiao, Y., Zhang, B., Cheng, Z., Shi, J., Xiong, J., Li, Z., & Zhang, K. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00017 · Cited by 11
Self-citationToxicology of Oligonucleotide Therapeutics and Understanding the Relevance of the Toxicities
Levin, A. A., & Henry, S. P. (2010) · Wiley eBooks · doi:10.1002/9780470571224.pse183 · Cited by 11
Cited by
Chemically Modified Platforms for Better RNA Therapeutics
Shi, Y., Zhen, X., Zhang, Y., Li, Y., Koo, S., Saiding, Q., Kong, N., Liu, G., Chen, W., & Tao, W. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00611 · Cited by 172
Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges
Choucair, K., Imtiaz, H., Uddin, M. H., Nagasaka, M., Al-Hallak, M. N., Philip, P. A., El-Rayes, B., Pasche, B., & Azmi, A. S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02473-8 · Cited by 79
Lu, J., Dai, Y., He, Y., Zhang, T., Zhang, J., Chen, X., Jiang, C., & Lu, H. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.3c11914 · Cited by 51
New prospectives on treatment opportunities in RASopathies
Gelb, B. D., Yohe, M. E., Wolf, C. M., & Andelfinger, G. (2022) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.32024 · Cited by 42
Xue, L., Xiong, X., Zhao, G., Arocho, W. A. M., Palanki, R., Xiao, Z., Han, X., Yoon, I., Figueroa‐Espada, C. G., Xu, J., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c10265 · Cited by 43
Metadata
- Authors
- Wang, D., Wang, Q., Wang, Y., Chen, P., Lu, X., Jia, F., Sun, Y., Sun, T., Zhang, L., Che, F., He, J., Lian, L., Morano, G., Shen, M., Ren, M., Dong, S. S., Zhao, J. J., & Zhang, K.
- Affiliations
- Northeastern University (US)
- Harvard University (US)
- Koch Institute for Integrative Cancer Research At MIT (US)
- Corresponding author
- Zhao, Jean J.
- Zhang, Ke
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2022-07-14
- Volume
- 119
- Issue
- 29
- Pages
- e2113180119-e2113180119
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC9304022
- OpenAlex
- W4285387133
- Cited by
- 43
- References
- 57
- Citations by year
- 2026: 10 · 2025: 10 · 2024: 12 · 2023: 5 · 2022: 6
- FWCI
- 2.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- HHS | NIH | National Cancer Institute (1R01CA251730)
- HHS | NIH | National Institute of General Medical Sciences (1R01GM121612)
- National Science Foundation (2004947)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Materials Science › Polymers and Plastics › Dendrimers and Hyperbranched Polymers
- Keywords
- KRAS mutation, antisense oligonucleotides, bottlebrush polymers, molecular brushes, non-small cell lung cancer, pharmacokinetics, tumor uptake, antitumor efficacy, drug delivery
- MeSH terms
- Animals, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Polyethylene Glycols, Proto-Oncogene Proteins p21(ras), Oligonucleotides, Antisense, Xenograft Model Antitumor Assays, Mice, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.